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Brain serotonin synthesis capacity in
obsessive-compulsive disorder: effects of
cognitive behavioral therapy and sertraline
Jennifer I. Lissemore1, Debbie Sookman1,2, Paul Gravel3, Alexandre Berney1,3, Amir Barsoum4,5, Mirko Diksic3,
Thomas E. Nordahl6, Gilbert Pinard1, Igor Sibon1,3, Jean Cottraux7, Marco Leyton1,3 and Chawki Benkelfat1,3
Abstract
Cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) are both effective treatments for
some patients with obsessive-compulsive disorder (OCD), yet little is known about the neurochemical changes related
to these treatment modalities. Here, we used positron emission tomography and the α-[11C]methyl-L-tryptophan
tracer to examine the changes in brain regional serotonin synthesis capacity in OCD patients following treatment with
CBT or SSRI treatment. Sixteen medication-free OCD patients were randomly assigned to 12 weeks of either CBT or
sertraline treatment. Pre-to-post treatment changes in the α-[11C]methyl-L-tryptophan brain trapping constant, K* (ml/
g/min), were assessed as a function of symptom response, and correlations with symptom improvement were
examined. Responders/partial responders to treatment did not show significant changes in relative regional tracer
uptake; rather, in responders/partial responders, 12 weeks of treatment led to serotonin synthesis capacity increases
that were brain-wide. Irrespective of treatment modality, baseline serotonin synthesis capacity in the raphe nuclei
correlated positively with clinical improvement. These observations suggest that, for some patients, successful
remediation of OCD symptoms might be associated with greater serotonergic tone.
Introduction
Obsessive-compulsive disorder (OCD) is a chronic
mental illness involving intrusive, unwanted thoughts
(obsessions) and persistent mental or behavioral rituals
(compulsions) that cause significant deficits in social
functioning. Cognitive behavioral therapy (CBT) and
selective serotonin reuptake inhibitors (SSRIs) have, in
separate multicenter trials, demonstrated efficacy and
tolerability in the treatment of 40–60% of OCD
patients1,2. The success of SSRIs, relative to medications
targeting neurotransmitter systems other than serotonin
(5-hydroxytryptamine (5-HT)), suggests that the latter
may play a role in the remediation of OCD symptoms3,4.
Despite the documented effectiveness of these treatments,
changes in neurochemistry in vivo associated with CBT or
SSRI in OCD patients, including changes in the ser-
otonergic system, remain elusive.
Neuroimaging and neurosurgical studies have impli-
cated the cortico-striato-thalamo-cortical (CSTC) circuit
in OCD neurobiology5; indeed, effective OCD treatments
with either SSRIs, clomipramine, or behavior therapy,
alone or in combination, have been reported to decrease
abnormally elevated CSTC circuit activity6,7. Notably,
however, conflicting findings have been reported,
including increased activity within CSTC circuitry fol-
lowing successful OCD treatment8. Positron emission
tomography (PET) and single photon emission computed
tomography (SPECT) studies have investigated more
specific aspects of neurotransmission within CSTC cir-
cuitry, including measuring 5-HT transporter (5-HTT)
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and receptor binding, using tracers such as [11C]DASB,
[123I]β-CIT, [11C]McN 5652, and [11C]MDL100907. Pre-
treatment, baseline abnormalities in 5-HTT and 5-HT2A
receptor availabilities within CSTC circuitry have been
reported in OCD patients9–11, although there has been
considerable variability12–14.
To date, few studies have investigated changes in the
serotonergic system during OCD treatment. Early studies
found changes in cerebrospinal fluid 5-HT metabolite
levels and blood platelet 5-HTT levels pre–post treat-
ment15, but these findings have not been replicated16, and
peripheral 5-HT measures cannot be used to study brain
regional changes in serotonergic functioning. To our
knowledge, only one study has investigated within-subject
brain regional changes in the serotonergic system in OCD
patients before and after treatment: Zitterl et al. reported
a significant reduction in 5-HTT availability in the tha-
lamus/hypothalamus of OCD patients, using SPECT and
[123I]β-CIT, following 12 weeks of clomipramine treat-
ment17. Similar decreases during repeated exposure to
SSRIs in various pathological and non-pathological con-
ditions were also reviewed17. To our knowledge, no stu-
dies have explored the effects of CBT on the serotonergic
system in OCD patients. Moreover, 5-HTT imaging has
been interpreted by many to reflect density of innervation,
rather than functional status per se18.
The PET tracer α-[11C]methyl-L-tryptophan (α-[11C]
MTrp) is thought to reflect central 5-HT metabolism in
humans in vivo19,20. α-[11C]MTrp is analogous to the 5-
HT precursor, L-tryptophan, except that it is not incor-
porated into protein21. After crossing the blood-brain
barrier, α-[11C]MTrp is taken up into serotonergic neu-
rons, and ultimately is metabolized into α-M-5-HT. α-M-
5-HT is not degraded by monoamine oxidase and cannot
cross the blood–brain barrier, thereby accumulating in
serotonergic neurons. The net blood-to-brain clearance of
the tracer is used to calculate the α-[11C]MTrp trapping
(unidirectional uptake) constant, K* (in ml/g/min). α-
[11C]MTrp has been used to study 5-HT synthesis capa-
city, and more generally, 5-HT metabolism, in various
patient populations22–24. In particular, we previously used
α-[11C]MTrp to study baseline 5-HT synthesis capacity
rates in OCD patients, and reported abnormally elevated
α-[11C]MTrp trapping, relative to controls, in temporal,
striatal, and limbic regions25.
As a follow-up to our baseline study of treatment-free
OCD patients, the present study investigated the effects of
drug treatment or CBT on brain regional 5-HT synthesis
capacity. OCD patients were randomly assigned to either
CBT or SSRI monotherapy (sertraline), and α-[11C]MTrp
PET scans were repeated following 12 weeks of treatment.
The goals of the present study were to (i) compare
regional 5-HT synthesis capacity in OCD patients before
and after treatment with CBT or sertraline, and (ii)
identify brain regions where pre-treatment regional 5-HT
synthesis capacity is associated with treatment outcome.
Here, we expected that changes in α-[11C]MTrp uptake,
particularly within CSTC circuitry, would relate to
changes in obsessive-compulsive, but not mood, symp-
toms. However, as the first study of treatment-related
changes in serotonin synthesis capacity in OCD patients,
the current study was designed to be primarily explora-
tory in nature.
Materials and methods
Study population
Patients were referred by the OCD Clinic, Department
of Psychology, McGill University Health Center (MUHC),
having participated in a baseline PET study prior to
beginning treatment25. Exclusion criteria included: (1)
personal or family history of Tourette’s syndrome; (2)
history of other Axis I disorders, except for depression
secondary to OCD, as assessed using the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID)26;
(3) current or past substance abuse or dependence; (4)
current or past use of 3,4-methylene-dioxy-methamphe-
tamine (MDMA) or methylene-dioxy-amphetamine
(MDA); and (5) history of allergy or treatment resis-
tance to sertraline. All patients, at entry into the study,
were medication-free for at least 3 weeks or more than
five elimination half-lives of the drug, whichever was
longer. Most patients were medication-free for con-
siderably longer; of eight patients previously treated with
antidepressants, seven were drug-free >6 months at entry
into the study.
After inclusion in the study, the patients were randomly
assigned (using a block randomization design with blocks
of 4) to receive CBT or sertraline treatment for a period of
12 weeks. OCD symptom severity, assessed using the
Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and
depressive symptoms, estimated with the Beck Depression
Inventory (BDI), were recorded by a clinician blind to the
patient’s PET data approximately every 2 weeks during
treatment, beginning at baseline (week 0). Following
completion of the 12-week treatment study, patients in
both groups were offered further treatment as clinically
indicated.
All participants provided written, informed consent.
The study was carried out in accordance with the
Declaration of Helsinki, and was approved by the
Research Ethics Committee of the Montreal Neurological
Institute (MNI) and the Institutional Review Board of
McGill University.
Treatment
Patients assigned to sertraline treatment received an
initial dose of 25 mg/day. Sertraline was provided in an
open fashion, as 25 mg capsules ingested once daily, in the
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morning with food. After 1 week of treatment, unless
limited by side effects, the daily dose was increased to
50mg/day. If, after a second week, the patient’s ther-
apeutic response did not show evidence of symptomatic
improvement, this dose was increased to 100 mg/day
unless limited by side effects. A third increase in dose to
150mg/day after another 2 weeks (week 4) and a final
increase to 200mg/day (week 6) were each made if
response remained unsatisfactory (<20% decrease in Y-
BOCS score). The final mean ± SD daily dose of sertraline
was 133 ± 52 mg/day, and all patients were prescribed a
stable dose of medication during the last 2 weeks of the
study.
Patients assigned to CBT received two 90-min indivi-
dual sessions per week for 12 weeks. Specialized CBT was
designed and administered under the close supervision of
DS, an experienced OCD expert clinician and supervisor.
The specialty multidimensional CBT program was indi-
vidualized for each patient and included: psycho-educa-
tion; cognitive therapy to collaboratively modify
symptom-related appraisals and meanings of intrusive
thoughts and feared situations; strategies for dysfunc-
tional cognitive–emotional processing, intolerance of
distress, and overestimation of threat; exposure and
response prevention (ERP) and behavioral experiment
protocols designed to optimize adaptive learning; self-
directed, between-session homework with attention to
treatment adherence; and interventions for relapse pre-
vention, resilience, and self-efficacy. Therapist-assisted
ERP and behavioral experiments were administered in
patients’ home as needed. Interventions specifically tar-
geted the symptom subtype characteristics for each case27.
PET and magnetic resonance imaging (MRI)
PET scans were performed before and after 12 weeks of
treatment. PET and MRI procedures were carried out as
per Berney et al.25. Briefly, in order to minimize variability
between scans in plasma concentrations of amino acids,
such as tryptophan, a low-protein diet followed by an
overnight fast was required of participants before scan-
ning days28. On PET scan days, all participants tested
negative on a urine drug screen sensitive to cocaine,
opiates, phencyclidine, cannabinoids, barbiturates, ben-
zodiazepines, and amphetamines (Triage Panel for Drugs
of Abuse, Biosite Diagnostics, CA, USA). Additionally,
women of fertile age were scanned during their follicular
phase, due to previous findings of changes in serotonergic
activity in different phases of the estrous cycle in rats29
and the menstrual cycle in women30.
α-[11C]MTrp was produced as described elsewhere31.
PET scanning was performed using an ECAT HR+
scanner (CTI/Siemens, Knoxville, TN; 3D mode with a
resolution of 5 × 5 × 5mm full width at half maximum
(FWHM)) in the late morning/early afternoon. After a
transmission scan for attenuation correction using a 68Ge/
Ga source, α-[11C]MTrp was injected intravenously over
2 min (mean ± SD= 9.6 ± 0.8 mCi), and a 60-min dynamic
image acquisition scan was performed. Thirteen venous
blood samples were collected to compute the α-[11C]
MTrp input function, as described previously32,33. Five
plasma samples were used to measure free and total
plasma tryptophan concentrations using high-
performance liquid chromatography.
Each participant also underwent a T1-weighted MRI
scan for PET-MR co-registration using a 1.5 T Philips
Gyroscan scanner (Philips Medical Systems, Eindhoven,
Netherlands; 3D fast-field echo scan: TR= 18 ms; TE=
10ms; FA= 30°; 256 × 256 × 160mm matrix; 1 mm3 iso-
tropic resolution).
Calculation of α-[11C]MTrp trapping (K*)
The Patlak graphic approach34 was used to calculate
absolute K* values (ml/g/min), using dynamic PET data
collected 20–60min after tracer injection32,33 and per-
ipheral metabolite values. To account for any effect of
global differences in α-[11C]MTrp trapping on regional
values, relative regional K* values were calculated by
normalizing absolute regional K* values to global K*
values (defined as the mean K* value for gray matter).
Given that both relative and absolute K* values were
previously reported to be stable over several weeks within
an individual35, we also examined within-subject changes
in absolute regional K* values. Pre- and post-treatment
comparisons of regional and global K* values were carried
out using both Statistical Parametric Mapping (SPM) and
an MRI-based region of interest (ROI) method.
Voxel-based analysis using SPM
Brain-wide voxel-wise analyses comparing K* values
pre- and post-treatment were carried out using SPM12
(Wellcome Functional Imaging Laboratory). K* images
were spatially normalized into MNI-305 stereotaxic space,
using an algorithm described elsewhere36, and then
smoothed using a 14-mm FWHM Gaussian filter to
reduce the effect of anatomical variability. The t-test was
applied voxel by voxel. The height threshold used to
interpret the t-test in terms of probability level was set at
p < 0.001, uncorrected for multiple comparisons, with an
extent threshold of 100 voxels, as previously25, then at 50
voxels for exploratory analyses. The t-map threshold was
T8= 4.50 for responders/partial responders and T5= 5.89
for non-responders.
MRI-based ROI analysis
Pre–post treatment changes in regional K* values were
also analyzed using an a priori MRI-based ROI approach.
Each patient’s MRI data were corrected for field inho-
mogeneities and spatially normalized into MNI-305
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stereotaxic space. Using an automatic segmentation
method37,38, ROIs were defined in the left and right
caudate, hippocampus, inferior temporal gyrus, cingulate,
lateral and medial prefrontal cortices, nucleus accumbens,
putamen, and thalamus. ROIs were smoothed using a
7 mm FWHM Gaussian filter and resampled into PET
acquisition space. Time–activity curves were then derived
by applying the ROIs to dynamic native PET space.
Results
Demographics
Sixteen patients with a diagnosis of OCD as per the
SCID26 were included in the study. After randomization,
eight patients received CBT (6M/2F), and eight sertraline
(6M/2F). Data from a post-treatment PET scan were not
available for one male patient treated with CBT for
technical reasons, therefore a total of 15 patients was
included in all PET analyses (11M/4F; mean ± SD age=
34.4 ± 9.3 years).
The demographic and clinical characteristics of the
OCD patients are summarized in Table 1 for each treat-
ment subgroup, and in Supplementary Table 1 for each
clinical response subgroup. No significant differences in
age, Y-BOCS score, or BDI score were found prior to
treatment between treatment subgroups, or between
subgroups of “responders & partial responders” vs. “non-
responders”.
Clinical response
We observed a progressive improvement in mean Y-
BOCS scores for both treatment groups, as illustrated in
Fig. 1. At 12 weeks of continuous monitoring of clinical
response, seven patients were deemed responders to
treatment (≥35% decrease in Y-BOCS score), and three
patients were deemed partial responders to treatment
(≥25% but ≤35% reduction in Y-BOCS score)39; these 10
patients were combined into a group of responders/partial
responders to treatment for all analyses (4 CBT/6 SSRI;
mean ± SD % decrease in Y-BOCS score= 52.5 ± 20.1).
Six patients were deemed non-responders to treatment (4
CBT/2 SSRI; <25% decrease in Y-BOCS score; mean ± SD
% decrease= 1.9 ± 22.4). Overall, there was a significant
decrease in Y-BOCS scores pre–post treatment (two-
tailed paired t-test; t15= 4.49, p < 0.001); there was no
significant difference between CBT and SSRI treatment
groups in the pre–post % change in Y-BOCS scores (two-
tailed independent t-test, t14= 0.72, p= 0.48). In the
whole sample, BDI scores pre–post treatment decreased
significantly (Wilcoxon signed-rank test, Z=−2.2, p=
0.026), though the effect was clinically minimal.
Global and regional α-[11C]MTrp trapping
Using SPM analysis, the functional images of all OCD
patients from pre- and post-treatment conditions were
first compared (Pre > Post and Pre < Post). No significant
changes in relative (normalized) or absolute regional K*
values were observed when treatment groups were com-
bined. Accordingly, no ROIs demonstrated a significant
pre–post change in relative or absolute K* values in the
ROI-based analyses, and further, there was no significant
pre–post change in global K* values in the whole patient
sample. Similarly, when pre- and post-treatment α-[11C]
MTrp trapping was compared within each treatment
group separately (sertraline or CBT), no relative or
absolute regional or global changes in K* values were
identified.
Next, we compared pre- and post-treatment α-[11C]
MTrp trapping in the sub-sample of responders/partial
responders (n= 9) and non-responders (n= 6). Using
SPM and ROI-based analyses, again, no significant
pre–post changes in relative regional K* values were
identified in treatment responders. However, responders/
Table 1 Patient demographics
Characteristic CBT (n= 8) SSRI (n= 8)
Age, y
Mean (SD) 33.7 (9.5) 33.4 (8.5)
Range 23–53 18–45
Responders/partial
responders
4/8 6/8
Early-onset OCD (≤10 y), No. 5 5
Predominant compulsion, No.
Washing 4 4
Checking 4 4
Lifetime history of MDE (2° to
OCD symptoms), No.
2 3
Past substance abuse, No. 0 0
Pre Post Pre Post
Y-BOCS score, mean (SD) 23 (4.4) 15.8 (7.5) 23.6
(5.6)
14.7 (8.2)
BDI score, mean (SD) 9.8 (4.5) 6.9 (6.0) 14.1
(11.2)
7.6 (9.5)
Plasma free tryptophan,
mean (SD), nmol/La
10.3 (2.6) 8.4 (1.4) 9.8 (1.7) 9.3 (2.1)
Global K*, mean (SD), mL/g/
mina
5.1 (1.3) 6.1 (1.5) 5.8 (1.3) 6.07 (2.0)
Intravenously injected, mean
(SD), mCia
9.3 (1.1) 9.6 (0.7) 9.6 (0.8) 9.7 (0.4)
Responders/partial responders demonstrated a >25% decrease in Y-BOCS score
OCD obsessive-compulsive disorder, CBT cognitive behavioral therapy, SSRI
selective serotonin re-uptake inhibitor, MDE major depressive episode, Y-BOCS
Yale-Brown Obsessive Compulsive Scale, BDI Beck Depression Inventory, No.
number
aData not included for one patient treated with CBT
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partial responders demonstrated a significant increase in
global K* values pre–post treatment (two-tailed paired t-
test, t8= 3.05, p= 0.016; mean increase of 29.7%, Cohen’s
d= 1.02), whereas non-responders showed no significant
treatment-related changes in global K* values (two-tailed
paired t-test, t5= 0.63, p= 0.55; mean decrease of 6.4%).
Pre-treatment values of global K* did not differ sig-
nificantly between responders/partial responders and
non-responders. Correspondingly, voxel-wise analyses
identified brain-wide increases in absolute K* values (right
» left; yet, increases in absolute K* values were observed
bilaterally in the ROI analyses, see Supplementary Figure
1) in responders/partial responders pre–post treatment
(Fig. 2a). By contrast, no changes in absolute K* values
were observed in non-responders, pre–post treatment
(Fig. 2b).
A three-way Time × ROI × Response repeated measures
ANOVA yielded a significant Time × Response interac-
tion (F1,13= 5.67, p= 0.033) but not a three-way inter-
action (p= 0.61), indicating that the effects did not differ
in the separate ROIs. Consistent with this, the change in
global K* values pre–post treatment was significantly
greater in the responders/partial responders than the non-
responders (two-tailed independent t-test, t13= 2.37, p=
0.034, Hedges’ g= 1.25).
Correlations between α-[11C]MTrp trapping and clinical
scores
Using SPM analysis and ΔY-BOCS scores as a covariate,
we evaluated the correlation between ΔY-BOCS scores
and pre-treatment K* values in the whole patient sample.
Both baseline K* and ΔY-BOCS values were normally
distributed. Improvement in Y-BOCS scores correlated
positively with baseline α-[11C]MTrp trapping in the
raphe nuclei within the right midbrain (t13= 6.66, k= 67
voxels, coordinates x, y, z= 6, −20, −22mm) indepen-
dent of treatment modality (Fig. 3).
Consistent with the global K* value findings in clinical
response sub-groups, pre–post treatment changes in
global K* values (ΔK*Global) correlated positively with %
decrease in Y-BOCS scores (rs= 0.46, p= 0.08), as shown
in Fig. 4. Notably, there was a clear outlier in this corre-
lation, and when the outlier was removed, the correlation
reached significance (rs= 0.67, p= 0.009). ΔBDI scores
did not correlate with pre–post treatment changes in
global K* values (rs=−0.01, p= 0.96) or with ΔY-BOCS
scores, suggesting that concurrent changes in depressive
symptoms were unlikely to have driven the reported
results.
Discussion
In this study, three distinct observations were made: (i)
the SSRI sertraline and specific cognitive behavior therapy
markedly reduce obsessive compulsive symptoms, (ii) this
effect, though robust and significant, seldom does achieve
full remission, and (iii) this effect is associated with a
significant pre–post increase in whole-brain 5-HT
synthesis capacity in those patients who respond to either
treatment. Moreover, in the whole patient sample,
increases in global 5-HT synthesis capacity correlated
with reductions in OCD symptom severity. Regional
changes in absolute α-[11C]MTrp trapping also revealed
widespread increases in 5-HT synthesis capacity in
responders and partial responders to either CBT or SSRI
treatment (Supplementary Figure 1). Collectively, these
findings support a primarily brain-wide, rather than
localized, enhancement of central 5-HT synthesis capacity
during effective cognitive-behavioral or sertraline (SSRI)
treatment in OCD.
The reductions in obsessive-compulsive symptoms
observed here are in line with previous reports of SSRI or
CBT efficacy in OCD patients1,2. However, whereas seven
patients achieved symptom remission, as defined by a Y-
BOCS score ≤ 1239, nine patients did not remit following
12 weeks of conventional treatment. A greater under-
standing of the mechanisms that support symptom
reduction is critical to treatment optimization, the ulti-
mate goal being to leverage these mechanisms to achieve
higher rates of remission in OCD patients. To this end,
the current study emphasizes the importance of func-
tional changes to brain 5-HT neurotransmission in the
control of obsessive-compulsive symptoms, likely in
conjunction with other neurotransmitters.
Independent of treatment modality, greater improve-
ment in OCD symptoms with SSRI or CBT was also
associated with higher pre-treatment 5-HT synthesis
Fig. 1 OCD symptom improvement over time with CBT or
sertraline treatment. Change in mean Y-BOCS scores during
12 weeks of CBT or sertraline treatment, as measured approximately
every 2 weeks. Y-BOCS Yale-Brown Obsessive Compulsive Scale, CBT
cognitive behavioral therapy, SSRI selective serotonin re-uptake
inhibitor
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capacity in the raphe nuclei. The dorsal and median raphe
nuclei are midbrain structures that contain the major
serotonergic populations40. 5-HT is produced by the
raphe nuclei, and ascending serotonergic projections from
the dorsal/median raphe project to most of the brain41,
including CSTC circuitry implicated in OCD neuro-
pathology. The observed correlation between clinical
response and baseline 5-HT neurotransmission therefore
prompts speculation that elevated 5-HT synthesis capa-
city in the raphe nuclei prior to treatment facilitates
Fig. 2 Pre–post treatment increases in serotonin synthesis capacity in responders/partial responders and non-responders. Maximum
intensity projections of the t-values, showing brain regions where absolute K* values (K*Absolute) were higher post-treatment compared to pre-
treatment in clinical response sub-groups. a Responders and partial responders to either CBT or SSRI treatment (n= 9) demonstrated widespread
pre–post treatment increases in absolute regional K* values. b Non-responders (n= 6) did not show any significant pre–post changes in absolute
regional K* values. For visualization purposes, the displayed t-map threshold was T8= 3.4 for responders/partial responders and T5= 4.0 for non-
responders, with p= 0.005 and an extent threshold of 50 voxels
Fig. 3 Positive correlation between baseline K* values and OCD symptom improvement. Statistical parametric maps (SPM12), with an
anatomical MRI overlay, demonstrating brain regions where pre-treatment K* values correlated positively with ΔY-BOCS in the whole sample of OCD
patients (n= 15). The t-map threshold was 3.85, with p= 0.001 and an extent threshold of 50 voxels. A significant cluster was found in the right
rostral raphe nuclei (t13= 6.66, k= 67 voxels, coordinates x, y, z= 6, −20, −22 mm)
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increases in the terminal regions during clinical
improvement.
Taken together with our previous findings of abnor-
mally elevated brain regional 5-HT synthesis capacity in
OCD patients at baseline25, the results presented here
provide preliminary support for a serotonergic “braking
system” operative during successful therapeutics in OCD.
The current observations of further increases in 5-HT
synthesis capacity with effective treatment support a
compensatory, rather than pathological, role of 5-HT
neurotransmission in OCD. The serotonergic braking
system model posits that activation of the central ser-
otonergic system, prior to treatment, might connote an
unsuccessful attempt to inhibit obsessive-compulsive
symptoms. CBT or SSRI exposure in OCD patients that
respond to treatment could enhance this pre-existing
serotonergic braking system, such that it can more
effectively inhibit OC symptoms. Considering the
observed association between higher pre-treatment 5-HT
synthesis capacity in the raphe nuclei and greater clinical
response, standard OCD treatments may provide suffi-
cient support to this braking system in patients with
higher serotonergic functioning at baseline, therefore
enabling a therapeutic response. In line with the present
findings, long-term treatment with SSRIs has been found
to increase serotonergic neurotransmission in animals42–
44, and, more specifically, long-term administration of
sertraline has been shown to increase 5-HT synthesis in
the dorsal raphe nucleus of the rat45. Furthermore, as
reductions in brain 5-HTT expression are associated with
increased serotonergic neurotransmission46,47, findings of
reduced 5-HTT availability in OCD patients at baseline,
and further reductions in 5-HTT availability with clomi-
pramine or escitalopram treatment17,48, are also con-
sistent with a serotonergic braking system.
In psychiatry, it is often assumed that abnormal brain
processes will normalize to those of healthy controls with
successful treatment; for example, in depression, 5-HT
metabolism has been shown to be abnormally low at
baseline24 and to normalize (increase) with antidepressant
treatment49. Earlier brain functional imaging studies of
OCD patients have also demonstrated normalization (via
reduction) of glucose metabolism in OCD patients who
respond to either behavioral or drug therapy6,7. These
findings are not necessarily incongruous with the current
5-HT metabolism observations; for example, pharmaco-
logical manipulations that decrease glucose metabolism
have been associated with increases in 5-HT metabolism
in rodents50. Alternatively, the link between previous
glucose metabolism findings and the current 5-HT
metabolism findings in OCD could be mediated by
other neural mechanisms and neurotransmitters.
Indeed, neurotransmitters seldom act in isolation.
Other mechanisms and neurotransmitters, including
dopamine and glutamate, have been implicated in
OCD51,52, and likely interact with the serotonergic system
in OCD11,53,54. Dopamine, for example, is also an
important neurotransmitter in the CSTC circuit, and
hyperactive dopaminergic functioning within the striatum
has been associated with OCD11 and with compulsive
behaviors in animal models of OCD55. Although the
serotonergic findings reported here were brain-wide, our
ROI analyses revealed significant increases in 5-HT
synthesis capacity within CSTC circuitry following suc-
cessful treatment, including in the bilateral caudate (see
Supplementary Figure 1). It is possible that the 5-HT
braking system counteracts dopaminergic hyperactivity
within CSTC circuitry through serotonin–dopamine
interactions. Specifically, increased 5-HT synthesis capa-
city associated with successful CBT or SSRI treatment
may result in augmented 5-HT tonic inhibition of dopa-
mine activity, and thus a reduction in compulsive symp-
toms. Accordingly, clinical response to SSRI therapy in
OCD has been associated with reduced dopaminergic
activity in the basal ganglia56, and can be improved using
dopamine antagonist augmentation strategies57. Another
potential mechanism underlying the observed link
between elevated 5-HT metabolism and greater ther-
apeutic response could be the known trophic properties of
5-HT in the regulation of cell proliferation, differentia-
tion, and maturation58. In support of a potential
Fig. 4 Changes in global K* values vs. changes in OCD symptom
severity. Pre–post treatment changes in global K* values (ΔK*global)
correlated positively with % decrease in Y-BOCS scores (rs= 0.46, p=
0.08). Notably, there was a clear outlier in this correlation (with the
outlier removed, rs= 0.67, p= 0.009); the outlier (red circle) was not
included in the least-squares linear fit to the data shown here. Patients
treated with sertraline are represented by triangles, and patients
treated with CBT are represented by circles. The ΔY-BOCS score cut-off
for responder/partial responder and non-responder subgroups is
indicated with the dashed vertical line. Y-BOCS Yale-Brown Obsessive-
Compulsive Scale, rs Spearman’s rank correlation coefficient
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neurogenic mechanism mediating the relationship
between 5HT metabolism and effective treatment, 5-
HT1A receptor knockout mice showed impaired neuro-
genesis and were insensitive to the behavioral effects of
the SSRI fluoxetine59. It is also conceivable that non-
response to SSRI or CBT may invoke mechanisms and/or
neuromodulators other than serotonin. In such
treatment-refractory patients, alternative therapies such
as deep brain stimulation60 or SSRI augmentation with an
antipsychotic57 might be beneficial.
Some limitations of the current study should be con-
sidered. (I) Although well within the range of similar
studies in the field, the sample size is modest, thus
replication of these findings is critical. (II) OCD research
is often confounded by clinical and biological hetero-
geneity. Here, considerable attention was focused on
preventing contamination of the biological measure of
interest by non-specific factors; yet, controlling for all the
non-specific factors, known (sleep, mood, motor activity,
biological rhythms) or not yet known, is always difficult in
clinical behavioral research, in particular with widespread
neurotransmitters, such as serotonin. (III) Patients with
OCD may require longer-term treatment with specialty
CBT in order to optimize treatment response (see Sook-
man27 for review). Important differences in clinical and
physiological indices between the treatment groups may
have emerged following longer treatment duration. (IV)
Several patients had been previously treated with SSRIs
and/or behavioral therapy, although these patients were
free of treatment for 3–90 months prior to beginning the
study. Thus, we cannot formally exclude the possibility
that some of the observed modifications after CBT or
SSRI treatment were facilitated by previous treatments.
(V) The significance of the α-[11C]MTrp/PET method has
been discussed in some detail, and it has been suggested
that the method might measure the blood–brain barrier
transport of tryptophan rather than the synthesis of ser-
otonin61. These reservations have been addressed in sev-
eral studies and reviews from our group19,32,33,62–65 and
others20,66,67, and cross-validation studies support the
general consensus that brain regional α-[11C]MTrp trap-
ping provides an acceptable proxy for 5-HT synthesis.
(VI) It is unlikely that the observed pre–post treatment
differences in regional K* values could be attributed to
changes in cerebral blood flow due to treatment, since
tracers with a low plasma–brain rate constant, such as α-
[11C]MTrp, are insensitive to variations in cerebral blood
flow68.
In conclusion, the present study did not identify region-
specific changes in 5-HT synthesis capacity following
treatment with either sertraline or CBT for OCD. Yet, the
evidence that elevations in brain-wide serotonergic func-
tion co-varied with clinical response raises the intriguing
possibility that these increases in OCD are compensatory.
In this model, a serotonergic braking system, which is
unable to sufficiently inhibit dysfunctional mechanisms
prior to treatment, could become more engaged over the
course of successful treatment with either SSRI or CBT in
OCD, allowing OCD symptoms to be more effectively
controlled.
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